Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide

Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide

In a two-stage phase II study, 24 patients with first diagnosis of glioblastoma (GBM) were treated with dendritic cell (DC) immunotherapy associated to standard radiochemotherapy with temozolomide (TMZ) followed by adjuvant TMZ. Three intradermal injections of mature DC loaded with autologous GBM ly...

Повний опис

Бібліографічні деталі
Автори: Serena Pellegatta, Marica Eoli, Valeria Cuccarini, Elena Anghileri, Bianca Pollo, Sara Pessina, Simona Frigerio, Maura Servida, Lucia Cuppini, Carlo Antozzi, Stefania Cuzzubbo, Cristina Corbetta, Rosina Paterra, Francesco Acerbi, Paolo Ferroli, Francesco DiMeco, Laura Fariselli, Eugenio A. Parati, Maria Grazia Bruzzone, Gaetano Finocchiaro
Формат: Стаття
Мова:English
Опубліковано: Taylor & Francis Group 2018-04-01
Серія:OncoImmunology
Предмети:
glioblastoma
dendritic cells
immunotherapy
adjuvant chemotherapy
natural killer cells
Онлайн доступ:http://dx.doi.org/10.1080/2162402X.2017.1412901

Інтернет

http://dx.doi.org/10.1080/2162402X.2017.1412901

Схожі ресурси